• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: ETHICON INC. INTERCEED (TC7)7.6 CM X 10.2 CM; BARRIER, ABSORBABLE, ADHESION

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

ETHICON INC. INTERCEED (TC7)7.6 CM X 10.2 CM; BARRIER, ABSORBABLE, ADHESION Back to Search Results
Catalog Number M4350
Device Problem Adverse Event Without Identified Device or Use Problem (2993)
Patient Problem Obstruction/Occlusion (2422)
Event Date 05/13/2019
Event Type  Injury  
Manufacturer Narrative
(b)(4).To date the device has not been returned.If the device or further details are received at the later date a supplemental medwatch will be sent.Attempts are being made to obtain the following information.To date no response has been provided.If further details are received at a later date a supplemental medwatch will be sent.Please clarify what does ¿possible unrelated¿ mean? was this intestinal obstruction related to the interceed or not related? please specify.Are you indicating that the device is a potential cause of the reported intestinal obstruction? what does the doctor believe is the etiology of the intestinal obstruction outcome?.
 
Event Description
It was reported that the patient underwent a laparoscopic rectal carcinoma radical resection/dixon and preventive ileostomy procedure on (b)(6) 2019 and the absorbable adhesive barrier was used.The device was still retained in the patient when the intestinal obstruction occurred three days after the surgery, on (b)(6) 2019.It was reported that the patient required hospitalization or prolongation of existing hospitalization.In summary, it was reported the intestinal obstruction was definitely related to the surgery, and possible unrelated to the absorbable adhesive barrier.After the intestinal obstruction, the symptomatic treatment was conducted including gastrointestinal nutrition support.Then the patient healed and discharged about 1 week later.It was confirmed the event healed without sequela.It was also reported that the end date of outcome was (b)(6) 2019.Additional information has been requested.
 
Manufacturer Narrative
Method codes: 3331.The review of the batch manufacturing records was conducted, and the batch met all finished goods release criteria.Additional information was requested, and the following was obtained: please clarify what does ¿possible unrelated¿ mean?: unlikely.Was this intestinal obstruction related to the interceed or not related? please specify.: investigators judged unlikely.Are you indicating that the device is a potential cause of the reported intestinal obstruction?: investigators judged unlikely, it means the event is unlikely associated.What does the doctor believe is the etiology of the intestinal obstruction outcome?: it is mechanical incomplete intestinal obstruction.Relationship with phase 1 surgery: definitely related.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
INTERCEED (TC7)7.6 CM X 10.2 CM
Type of Device
BARRIER, ABSORBABLE, ADHESION
Manufacturer (Section D)
ETHICON INC.
p.o. box 151, route 22 west
somerville NJ 08876 0151
MDR Report Key8755023
MDR Text Key149845353
Report Number2210968-2019-83603
Device Sequence Number1
Product Code MCN
Combination Product (y/n)N
PMA/PMN Number
P880047
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type company representative,foreig
Type of Report Initial,Followup
Report Date 06/04/2019
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Operator Health Professional
Device Expiration Date04/30/2022
Device Catalogue NumberM4350
Device Lot Number3930918
Was Device Available for Evaluation? No
Initial Date Manufacturer Received 06/04/2019
Initial Date FDA Received07/02/2019
Supplement Dates Manufacturer Received07/08/2019
Supplement Dates FDA Received07/18/2019
Patient Sequence Number1
Patient Outcome(s) Hospitalization; Required Intervention;
Patient Age55 YR
-
-